Brief: Arcellx Says Three Deaths Due To Treatment-Emergent Adverse Events In Anito-Cel Study

Arcellx

09/12/2024 04:06

Dec 8 (Reuters) - Arcellx Inc  ACLX.O :
    * ARCELLX ANNOUNCES NEW POSITIVE DATA FOR ITS IMMAGINE-1
STUDY IN
PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TO BE
PRESENTED DURING AN ORAL PRESENTATION AT THE 66TH ASH ANNUAL
MEETING AND EXPOSITION
    * ARCELLX INC - THREE DEATHS DUE TO TREATMENT-EMERGENT
ADVERSE
EVENTS IN ANITO-CEL STUDY

Source text:  ID:nBw1mbqjpa 
Further company coverage:  ACLX.O 

 ((Reuters.Briefs@thomsonreuters.com;))